Hypermarcas (OTCMKTS:HYPMY - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $5.02, but opened at $4.79. Hypermarcas shares last traded at $4.74, with a volume of 973 shares trading hands.
Analyst Ratings Changes
Separately, Scotiabank upgraded shares of Hypermarcas to a "strong-buy" rating in a research note on Thursday.
View Our Latest Stock Report on HYPMY
Hypermarcas Stock Down 1.7%
The company's fifty day moving average price is $4.66 and its 200-day moving average price is $3.82. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. The stock has a market cap of $3.00 billion, a P/E ratio of 19.76 and a beta of 0.81.
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The company reported ($0.04) earnings per share for the quarter. Hypermarcas had a net margin of 12.51% and a return on equity of 6.95%. The business had revenue of $184.34 million for the quarter.
Hypermarcas Dividend Announcement
The firm also recently announced a dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, July 1st will be issued a dividend of $0.0345 per share. This represents a dividend yield of 2.81%. The ex-dividend date is Monday, June 30th. Hypermarcas's payout ratio is 58.33%.
About Hypermarcas
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Featured Articles
Before you consider Hypermarcas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.
While Hypermarcas currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
